| Literature DB >> 30868979 |
C Bourély1, G Cazeau2, N Jarrige2, A Leblond3, J Y Madec4, M Haenni4, E Gay2.
Abstract
Antimicrobial-resistant bacteria in dogs can be transmitted to humans and close contact between dogs and people might foster dissemination of resistance determinants. The aim of our study was to describe the antimicrobial resistance (AMR) pattern of the major causative agents of canine otitis - one of the most common diseases in dogs - isolated in France. Data collected between 2012 and 2016 by the French national surveillance network for AMR, referred to as RESAPATH, were analysed. Resistance trends were investigated using non-linear analysis (generalised additive models). A total of 7021 antibiograms were analysed. The four major causative agents of canine otitis in France were coagulase-positive staphylococci, Pseudomonas aeruginosa, Proteus mirabilis and streptococci. Since 2013, resistance to fluoroquinolones has been on the decrease in both P. aeruginosa and Staphylococcus pseudintermedius isolates. For P. aeruginosa, 19.4% of isolates were resistant to both enrofloxacin and gentamicin. The levels of multidrug resistance (acquired resistance to at least one antibiotic in three or more antibiotic classes) ranged between 11.9% for P. mirabilis and 16.0% for S. pseudintermedius. These results are essential to guide prudent use of antibiotics in veterinary medicine. They will also help in designing efficient control strategies and in measuring their effectiveness.Entities:
Keywords: Antimicrobial resistance; RESAPATH; canine otitis; multidrug resistance; time series
Mesh:
Substances:
Year: 2019 PMID: 30868979 PMCID: PMC6518499 DOI: 10.1017/S0950268818003278
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 2.451
Number of isolates collected from dogs with otitis between 2012 and 2016 by genus and bacterium identified
| Genus | Bacterial species | Number of isolates | Proportion of isolates (%) | Total number of isolates per genus |
|---|---|---|---|---|
| Coagulase-positive staphylococci | 2513 | 33.0 | 3133 | |
| 294 | 3.9 | |||
| Other | 326 | 4.3 | ||
| 2103 | 27.5 | 2315 | ||
| Other | 212 | 2.8 | ||
| 1039 | 13.6 | 1103 | ||
| Other | 64 | 0.8 | ||
| 447 | 5.9 | 1072 | ||
| Other | 625 | 8.2 |
Antibiotics tested and the corresponding antibiotic classes for each bacterial genus
| Bacterial genus | Antibiotic | Antibiotic class |
|---|---|---|
| Coagulase-positive staphylococci | Gentamicin | Aminoglycosides |
| Cefoxitin or cefovecin | Cephalosporins | |
| Enrofloxacin | Fluoroquinolones | |
| Trimethoprim-sulfamethoxazole | Folate pathway inhibitors | |
| Fusidic acid | Fusidanin | |
| Erythromycin | Macrolides | |
| Penicillin G | Penicillins | |
| Chloramphenicol | Phenicol | |
| Gentamicin | Aminoglycosides | |
| Enrofloxacin | Fluoroquinolones | |
| Gentamicin | Aminoglycosides | |
| Ceftiofur | Cephalosporins | |
| Enrofloxacin | Fluoroquinolones | |
| Trimethoprim-sulfamethoxazole | Folate pathway inhibitors | |
| Amoxicillin, | Penicillins | |
| Gentamicin | Aminoglycosides | |
| Enrofloxacin | Fluoroquinolones | |
| Trimethoprim-sulfamethoxazole | Folate pathway inhibitors | |
| Erythromycin | Macrolides | |
| Chloramphenicol | Phenicol | |
| Oxacillin | Penicillins |
Resistance of isolates from dogs with otitis in France over the period 2012–2016
| Bacterium | Antibiotic | Number of resistant isolates | Total number of isolates | Level of resistance (%) with 95% CI | Resistance trend from GAM model |
|---|---|---|---|---|---|
| Penicillin G | 1650 | 2409 | 68.5 (66.6–70.3) | Non-linear | |
| Cefovecin | 112 | 1187 | 9.4 (7.8–11.2) | – | |
| Erythromycin | 716 | 2401 | 29.8 (28.0–31.7) | Stationary | |
| Gentamicin | 337 | 2491 | 13.5 (12.2–14.9) | Stationary | |
| Enrofloxacin | 274 | 2115 | 13.0 (11.6–14.5) | Non-linear | |
| Fusidic acid | 108 | 1757 | 6.1 (5.2–7.4) | – | |
| Chloramphenicol | 196 | 700 | 38.9 (34.6–43.3) | – | |
| SXT | 297 | 2432 | 12.2 (10.9–13.6) | Stationary | |
| Penicillin G | 190 | 268 | 70.9 (65.1–76.3) | – | |
| Cefoxitin | 26 | 246 | 10.6 (7.0–15.1) | – | |
| Erythromycin | 80 | 265 | 30.2 (24.7–36.1) | – | |
| Gentamicin | 36 | 278 | 12.9 (9.2–17.5) | – | |
| Enrofloxacin | 32 | 267 | 12.0 (8.3–16.5) | – | |
| Fusidic acid | 17 | 148 | 11.5 (6.8–17.8) | – | |
| Chloramphenicol | 37 | 119 | 31.1 (22.9–40.2) | – | |
| SXT | 28 | 274 | 10.2 (6.9–14.4) | – | |
| Oxacillin | 112 | 778 | 14.4 (12.0–17.1) | – | |
| Erythromycin | 253 | 1021 | 24.8 (22.2–27.5) | – | |
| Gentamicin | 26 | 790 | 3.3 (2.2–4.8) | – | |
| Enrofloxacin | 627 | 997 | 62.9 (59.8–65.9) | – | |
| Chloramphenicol | 89 | 252 | 35.3 (29.4–41.6) | – | |
| SXT | 210 | 1013 | 20.7 (18.3–23.4) | – | |
| Gentamicin | 375 | 2096 | 17.9 (16.3–19.6) | Stationary | |
| Enrofloxacin | 1352 | 1996 | 67.7 (65.6–69.8) | Non-linear | |
| Amoxicillin | 284 | 982 | 28.9 (26.1–31.9) | – | |
| Ceftiofur | 24 | 987 | 2.4 (1.6–3.6) | – | |
| Gentamicin | 106 | 1034 | 10.3 (8.5–12.3) | – | |
| Enrofloxacin | 134 | 1013 | 13.2 (11.2–15.5) | – | |
| SXT | 232 | 1015 | 22.9 (20.3–25.6) | – |
Trimethoprim-sulfamethoxazole; ‘–’: no analysis performed (<25 isolates per time step).
Fig. 1.Trends for antimicrobial resistance in Staphylococcus pseudintermedius isolates from dogs with otitis during the period 2012–2016, on a bimonthly time step.
Fig. 2.Trends for antimicrobial resistance in Pseudomonas aeruginosa isolates from dogs with otitis during the period 2012–2016, on a bimonthly time step.
Proportions of isolates (in % with 95% CI) that were pan-susceptible, resistant to one or two antibiotics from different classes, multidrug-resistant and resistant to all classes of antibiotics considered for analysis over the period 2012–2016
| Bacterial species (total number of isolates) | Susceptibility patterns of isolates | Number of isolates | Proportion |
|---|---|---|---|
| Pan-susceptible | 248 | 23.3 (20.8–25.9) | |
| Resistant to one or two antibiotics classes | 597 | 56.0 (53.0–59.0) | |
| Multidrug-resistant | 221 | 20.7 (18.3–23.3) | |
| Resistant to the six classes of antibiotics considered | 2 | 0.2 (0.0–0.7) | |
| Pan-susceptible | 52 | 24.5 (18.9–30.9) | |
| Resistant to one or two antibiotics classes | 124 | 58.5 (51.5–65.2) | |
| Multidrug-resistant | 36 | 17.0 (12.2–22.7) | |
| Resistant to the six classes of antibiotics considered | 6 | 2.8 (1.0–6.1) | |
| Pan-susceptible | 183 | 28.7 (25.2–32.4) | |
| Resistant to one or two antibiotics classes | 373 | 58.4 (54.5–62.3) | |
| Multidrug-resistant | 82 | 12.9 (10.4–15.7) | |
| Resistant to the five classes of antibiotics considered | 4 | 0.6 (0.2–1.6) | |
| Pan-susceptible | 592 | 29.8 (27.8–31.8) | |
| Resistant to enrofloxacin and gentamicin | 304 | 15.3 (13.7–16.9) | |
| Pan-susceptible | 588 | 63.8 (60.6–66.9) | |
| Resistant to one or two antibiotics classes | 225 | 24.4 (21.7–27.3) | |
| Multidrug-resistant | 109 | 11.8 (9.8–14.1) | |
| Resistant to the five classes of antibiotics considered | 6 | 0.7 (0.2–1.4) |